LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $100.60.

Several brokerages have issued reports on LMAT. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Barrington Research reiterated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Roth Capital reiterated a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday. Finally, Cantor Fitzgerald boosted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. The trade was a 37.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bridget A. Ross sold 2,500 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the transaction, the director owned 2,916 shares in the company, valued at $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,815 shares of company stock worth $1,929,206 in the last ninety days. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Parkside Financial Bank & Trust increased its stake in shares of LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 287 shares during the last quarter. Cornerstone Planning Group LLC grew its stake in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the last quarter. First Horizon Corp acquired a new position in LeMaitre Vascular in the 3rd quarter valued at about $39,000. Geneos Wealth Management Inc. grew its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at about $47,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 1.1%

Shares of LMAT stock opened at $86.27 on Thursday. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58. The firm’s fifty day moving average price is $89.94 and its two-hundred day moving average price is $87.01. The firm has a market capitalization of $1.95 billion, a P/E ratio of 41.88, a PEG ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same period in the previous year, the business earned $0.52 EPS. The company’s revenue was up 15.0% compared to the same quarter last year. On average, equities analysts predict that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.